Placebo analgesia in patients with functional and organic abdominal pain: A fMRI study in IBS, UC and healthy volunteers

Gut

Volumn 64, Issue 3, 2015, Pages 418-427

  Schmid, Julia ^a   Langhorst, Jost ^b   Gaß, Florian ^a,b   Theysohn, Nina ^a   Benson, Sven ^a   Engler, Harald ^a   Gizewski, Elke R ^c   Forsting, Michael ^a   Elsenbruch, Sigrid ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; PLACEBO; SCOPOLAMINE BUTYL BROMIDE; SODIUM CHLORIDE;

ABDOMINAL PAIN; ADAPTATION; ADULT; ANALGESIA; ANTICIPATION; ANXIETY; ARTICLE; ASSOCIATION; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; COLON DILATATION; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IRRITABLE COLON; MALE; NERVE STIMULATION; PAIN INTENSITY; PAIN THRESHOLD; PLACEBO EFFECT; SALIVA LEVEL; SCORING SYSTEM; ULCERATIVE COLITIS; BRAIN; CASE CONTROL STUDY; CHEMISTRY; FUNCTIONAL NEUROIMAGING; INFLAMMATORY BOWEL DISEASE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; SALIVA;

ABDOMINAL PAIN; ADULT; ANALGESIA; BRAIN; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; DEPRESSION; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; HYDROCORTISONE; INFLAMMATORY BOWEL DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PAIN MANAGEMENT; PLACEBO EFFECT; SALIVA;

EID: 84922353959     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306648     Document Type: Article

References (49)

1. Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of placebo effects. Lancet 2010; 375:686-95.
2. Enck P, Bingel U, Schedlowski M., et al. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 2013; 12:191-204.
3. Kaptchuk TJ, Kelley JM, Conboy L.A., et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336:999-1003.
4. Vase L, Robinson ME, Verne G.N., et al. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005; 115:338-47.
5. Vase L, Robinson ME, Verne G.N., et al. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 2003; 105:17-25.
6. Price DD, Craggs J, Verne G.N., et al. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients. Pain 2007; 127:63-72.
7. Lee HF, Hsieh JC, Lu C.L., et al. Enhanced affect/cognition-related brain responses during visceral placebo analgesia in irritable bowel syndrome patients. Pain 2012; 153:1301-10.
8. Lu HC, Hsieh JC, Lu C.L., et al. Neuronal correlates in the modulation of placebo analgesia in experimentally-induced esophageal pain: a 3T-fMRI study. Pain 2010; 148:75-83.
9. Schmid J, Theysohn N, Gass F., et al. Neural mechanisms mediating positive and negative treatment expectations in visceral pain: A functional magnetic resonance imaging study on placebo and nocebo effects in healthy volunteers. Pain 2013; 154:2372-80.
10. Elsenbruch S, Kotsis V, Benson S., et al. Neural mechanisms mediating the effects of expectation in visceral placebo analgesia: an fMRI study in healthy placebo responders and nonresponders. Pain 2012; 153:382-90.
11. Elsenbruch S, Schmid J, Basler M., et al. How positive and negative expectations shape the experience of visceral pain: an experimental pilot study in healthy women. Neurogastroenterol Motil 2012; 24:914-e460.
12. Kotsis V, Benson S, Bingel U., et al. Perceived treatment group affects behavioral and neural responses to visceral pain in a deceptive placebo study. Neurogastroenterol Motil 2012; 24:935-e462.
13. Lieberman MD, Jarcho JM, Berman S, et al. The neural correlates of placebo effects: a disruption account. Neuroimage 2004; 22:447-55.
14. Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology 2013; 144:36-49.
15. Elsenbruch S, Rosenberger C, Enck P., et al. Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 2010; 59:489-95.
16. Elsenbruch S, Rosenberger C, Bingel U., et al. Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology 2010; 139:1310-19.
17. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298:82-6.
18. Herrmann-Lingen C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale (HADS)-Deutsche Version (2. Auflage). Bern: Hans Huber, 2005.
19. Morfeld M, Kirchberger I, Bullinger M. SF-36 Fragebogen zum Gesundheitszustand. Göttingen, Germany: Hogrefe, 2011.
20. Borkenau P, Ostendorf F. NEO-Fünf-Faktoren Inventar (NEO-FFI) nach Costa und McCrae. Göttingen, Germany: Hogrefe, 1993.
21. Schulz P, Schlotz W, Becker P. Das Trierer Inventar zum chronischen Stress. Göttingen, Germany: Hogrefe, 2004.
22. Flor H, Rudy TE, Birbaumer N, et al. [The applicability of the West Haven-Yale multidimensional pain inventory in German-speaking countries. Data on the reliability and validity of the MPI-D.]. Schmerz 1990; 4:82-7.
23. Singer S, Brähler E. Die "Sense of Coherence Scale" - Testhandbuch zur deutschen Version. Göttingen: Vandenhoeck & Ruprecht, 2007.
24. Reiss M, Reiss G. Zur Untersuchung der motorischen Asymmetrien. Fortschr Neurol Psychiat 2000; 68:70-9.
25. Laux L, Glanzmann P, Schaffner P., et al. Das state-trait-angstinventar. Theoretische grundlagen und handanweisung. Goettingen: Beltz, 1981.
26. Kong J, Gollub RL, Polich G, et al. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J Neurosci 2008; 28:13354-62.
27. Bingel U, Wanigasekera V, Wiech K., et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med 2011; 3:70ra14.
28. Wager TD, Rilling JK, Smith E.E., et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 2004; 303:1162-7.
29. Bingel U, Lorenz J, Schoell E., et al. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain 2006; 120:8-15.
30. Piche M, Chen JI, Roy M, et al. Thicker posterior insula is associated with disease duration in women with irritable bowel syndrome (IBS) whereas thicker orbitofrontal cortex predicts reduced pain inhibition in both IBS patients and controls. J Pain 2013; 14:1217-26.
31. Wilder-Smith CH, Schindler D, Lovblad K., et al. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 2004; 53:1595-601.
32. Larsson MB, Tillisch K, Craig A.D., et al. Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome. Gastroenterology 2012; 142:463-72.
33. Hubbard CS, Labus JS, Bueller J, et al. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. J Neurosci 2011; 31:12491-500.
34. Naliboff BD, Berman S, Chang L., et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003; 124: 1738-47.
35. Labus JS, Naliboff BD, Berman S.M., et al. Brain networks underlying perceptual habituation to repeated aversive visceral stimuli in patients with irritable bowel syndrome. Neuroimage 2009; 47:952-60.
36. Labus JS, Naliboff BN, Fallon J, et al. Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: a network analysis. Neuroimage 2008; 41:1032-43.
37. Berman SM, Naliboff BD, Suyenobu B, et al. Reduced brainstem inhibition during anticipated pelvic visceral pain correlates with enhanced brain response to the visceral stimulus in women with irritable bowel syndrome. J Neurosci 2008; 28:349-59.
38. Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 2000; 288:1769-72.
39. Davis KD, Taylor KS, Hutchison W.D., et al. Human anterior cingulate cortex neurons encode cognitive and emotional demands. J Neurosci 2005; 25:8402-6.
40. Vogt BA. Pain and emotion interactions in subregions of the cingulate gyrus. Nat Rev Neurosci 2005; 6:533-44.
41. Ringel Y, Drossman DA, Leserman J.L., et al. Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology 2008; 134:396-404.
42. Porcelli P, Bagby RM, Taylor G.J., et al. Alexithymia as predictor of treatment outcome in patients with functional gastrointestinal disorders. Psychosom Med 2003; 65:911-18.
43. Bertisch SM, Legedza AR, Phillips R.S., et al. The impact of psychological factors on placebo responses in a randomized controlled trial comparing sham device to dummy pill. J Eval Clin Pract 2009; 15:14-19.
44. Petersen GL, Finnerup NB, Norskov K.N., et al. Placebo manipulations reduce hyperalgesia in neuropathic pain. Pain 2012; 153:1292-300.
45. Bernstein CN, Niazi N, Robert M., et al. Rectal afferent function in patients with inflammatory and functional intestinal disorders. Pain 1996; 66:151-61.
46. Chang L, Munakata J, Mayer E.A., et al. Perceptual responses in patients with inflammatory and functional bowel disease. Gut 2000; 47:497-505.
47. Zhou Q, Verne GN. New insights into visceral hypersensitivity-clinical implications in IBS. Nat Rev Gastroenterol Hepatol 2011; 8:349-55.
48. Ludidi S, Conchillo JM, Keszthelyi D, et al. Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff. Neurogastroenterol Motil 2012; 24:729-6.
49. Keszthelyi D, Troost FJ, Masclee AA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 303:G141-54.